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Abstract
The relationship between telomeres, nevi and melanoma is complex. Shorter telomeres have been found to be associated
with many cancers and with number of nevi, a known risk factor for melanoma. However, shorter telomeres have also been
found to decrease melanoma risk. We performed a systematic analysis of telomere-related genes and tagSNPs within these
genes, in relation to the risk of melanoma, dysplastic nevi, and nevus count combining data from four studies conducted in
Italy. In addition, we examined whether telomere length measured in peripheral blood leukocytes is related to the risk of
melanoma, dysplastic nevi, number of nevi, or telomere-related SNPs. A total of 796 cases and 770 controls were genotyped
for 517 SNPs in 39 telomere-related genes genotyped with a custom-made array. Replication of the top SNPs was
conducted in two American populations consisting of 488 subjects from 53 melanoma-prone families and 1,086 cases and
1,024 controls from a case-control study. We estimated odds ratios for associations with SNPs and combined SNP P-values
to compute gene region-specific, functional group-specific, and overall P-value using an adaptive rank-truncated product
algorithm. In the Mediterranean population, we found suggestive evidence that RECQL4, a gene involved in genome
stability, RTEL1, a gene regulating telomere elongation, and TERF2, a gene implicated in the protection of telomeres, were
associated with melanoma, the presence of dysplastic nevi and number of nevi, respectively. However, these associations
were not found in the American samples, suggesting variable melanoma susceptibility for these genes across populations
or chance findings in our discovery sample. Larger studies across different populations are necessary to clarify these
associations.
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Introduction
Telomeres are chromatin structures located at the ends of
chromosomes, comprised of repeats of (TTAGGG)n and telomere-
binding proteins [1]. During DNA replication, the nucleotide
repeats are lost, making telomeres progressively shorter. When
a critical length is reached, cells enter into replicative senescence
or apoptosis. If the cell can bypass the cell-cycle checkpoint with
the ability to continue dividing, chromosomal instability and/or
cancer can occur [1].
Melanocytic nevi (benign and dysplastic) are strong risk factors
for cutaneous melanoma [2–4]. Benign melanocytic nevi are
transient proliferations of melanocytes. After a replication phase,
melanocytes within nevi seem to enter into replicative senescence
and rarely experience apoptosis [5]. It is thought that they remain
in this state for decades and only a few progress to melanoma for
reasons that are not well understood [3]. It is possible that shorter
telomere length in melanocytes within nevi may trigger the entry
into senescence by limiting cell proliferation. This could in turn
affect the capacity for malignant transformation or proliferation of
malignant clones within nevi and thus the risk of melanoma. In
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fact, two prospective studies have reported that shorter telomeres
were associated with a decreased risk of melanoma [6,7].
However, telomere length has been found to be positively
correlated with the number and size of nevi in a cross-sectional
study in the UK [8].
Telomere length regulation is a highly complex process
requiring numerous proteins. One previous study assessed the
relationship between genetic variants in five telomere genes and
the risk of melanoma and found two single nucleotide polymorph-
isms (SNPs) in TERT and one in TRF1 to significantly increase
the risk of melanoma [9]. However, only five genes related to
telomere maintenance were included in that study, but more than
30 genes are involved in the telomere biology. Furthermore, the
study was limited by the relatively small number of melanoma
cases (N= 218).
In the current study, we combined data from three case-control
studies and one family study conducted in Italy, a Mediterranean
population generally characterized by a wide range of pigmenta-
tion characteristics, intense sun exposure and lower incidence rates
of melanoma in comparison to those found in the US and
Australia [10]. We examined the associations of 39 genes related
to the biology of telomeres, and 475 SNPs within these genes, with
the risk of melanoma. We evaluated the top findings in two
different American populations. In addition, we explored whether
these genes were related to the presence of dysplastic nevi (defined
as 5 mm or larger, predominantly flat, and with at least two of the
following characteristics: variable pigmentation, indistinct borders,
and an irregular outline [11,12]) and to nevus count in control
subjects. We also explored whether number of nevi or presence of
dysplastic nevi interact with SNPs in telomere biology genes, to
assess whether genetic susceptibility has a role in the progression
between nevi and melanoma. Finally, we tested for the association
between telomere length and the risk of melanoma, nevus count,




The study was approved by the Bufalini Hospital, the University
of L’Aquila, the Genoa San Martino Hospital and the National
Cancer Institute Ethics Committees and written informed consent
was obtained from all participants.
Study Populations
Subjects from three case-control studies of sporadic melanoma
and one study of familial melanoma conducted in Italy were
analyzed. The methods for the first case-control study (CCS1)
have been previously described [13,14]. Briefly, cases were
incident sporadic melanoma patients, without a family history of
melanoma, aged 17–77, negative for the CDKN2A/CDK4
mutations, diagnosed between December 1994 and January
1999 at the Dermatology Unit of Maurizio Bufalini Hospital in
Cesena, a referral point for the Emilia-Romagna and Northern
Marche regions in Northern Italy. During the study period, the
Bufalini Hospital examined approximately 85% of all melanoma
patients diagnosed in the area, as verified by comparison of patient
lists with the Romagna region cancer registry and with records of
melanoma diagnoses from the main hospitals of the area. Controls
were spouses or close friends of the cases, patients treated at the
same hospital for minor accidental trauma or healthy hospital
personnel recruited during the same period without a history of
melanoma and coming from the same geographical areas as the
cases. Controls were frequency-matched by age and gender to
cases. A single dermatologist (D.C.) performed skin examinations
for all study subjects to determine pigmentation characteristics,
freckles, nevus count (on the back only), presence of dysplastic
nevi, as well as other skin traits. Questionnaires were adminis-
trated to participants to obtain information on demographic
characteristics, family and medical history and sun exposure
behaviors. A total of 227 cases and 173 controls with blood
samples were included in the present study.
The methods for the second case-control study (CCS2) have
also been published [15]. Briefly, sporadic melanoma patients (not
tested for the CDKN2A/CDK4 mutations), diagnosed at the
Departments of Dermatology of the Universities of L’Aquila,
Florence or Modena in central Italy, aged 17–82, were recruited
between 2000 and 2002. Subjects treated for diseases unrelated to
melanoma at the Surgery and Internal Medicine Departments of
the corresponding Universities were recruited as controls for the
study. They were frequency matched by sex and age (61 year)
and study area. Information on demographic characteristics,
family and medical history, sun exposure, and pigmentation nevi
was collected using a standardized questionnaire. Clinical exam-
ination of all subjects was performed by two dermatologists (K.P.
and M.C.F.). A total of 264 cases and 165 controls with blood
samples were included in the present study.
The third case-control study (CCS3) was of sporadic melanoma
cases diagnosed between 2000–2007 at the units of dermatology,
medical oncology and plastic surgery of the National Cancer
Research Institute and San Martino Hospital, Genoa, in Northern
Italy [16]. Melanoma cases were older than 18 years of age,
without family history of melanoma and negative for the
CDKN2A/CDK4 mutations. Similarly, subjects without a history
of melanoma, older than 18 years of age were recruited at the
same hospital during the same period. A trained interviewer
obtained information from study subjects on demographic
characteristics, family and medical history, sun exposure, and
pigmentation characteristics using a standardized questionnaire.
All melanoma cases and 54.8% of the controls were also examined
by experienced dermatologists or plastic surgeons that also filled
out the questionnaire. The study was approved by the A total of
207 cases and 207 controls with blood samples were included in
the present study.
Finally, the familial melanoma study (FS) consists of 62 families
from Northern Italy with at least two relatives diagnosed with
melanoma who were recruited at the Dermatology Unit of
Maurizio Bufalini Hospital in Cesena [17]. Some of the melanoma
cases were deceased at the time of recruitment and so blood
samples were obtained from 96 melanoma patients and 225
unaffected individuals. The protocol for skin examination and
questionnaire administration was identical to CCS1, although the
questionnaires differed slightly.
Gene and SNP Selection and Genotyping
Thirty-nine genes coding for proteins that are known to directly
interact with telomeres or to regulate these proteins were selected
for our study, following Mirabello et al. [18] (Table S1). TagSNPs
in these genes and surrounding regions, comprising of 20kb
upstream of the 59 of each gene and 10kb downstream of the 39 of
each gene, were selected if they had a minor allele frequency
(MAF) larger than 5% and pairwise correlation (r2) smaller than
0.80 in the HapMap2 Project database. In total, 747 SNPs were
selected for genotyping using an iSelect Illumina Infinium custom
array at the NCI Core Genotyping Facility [19]. Two hundred
and thirty SNPs were excluded due to failing the assay (n = 93),
being monoallelic (n = 1), having less than 90% completion
(n= 93), having less than 95% concordance (n = 5), not possible
Telomeres, Nevi and Melanoma
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to genotyped in the custom array (n = 20) or having Hardy-
Weinberg equilibrium (HWE) less than 0.05/20,809 (n= 18), with
20,809 being the total number of non-failing SNPs in the iSelect
Illumina Infinium array. A total of 517 SNPs were genotyped.
Analyses were restricted to SNPs with MAF of at least 1% in
controls, resulting in 476 SNPs.
Replication Data Sets
Two datasets were used to verify whether the associations found
in the Mediterranean population were also present in American
subjects who differed by residence, sun exposure, pigmentation
characteristics and family history of melanoma. The first was
a family study comprised of 562 individuals (183 melanoma cases)
from 53 melanoma-prone families (23 of which had CDKN2A
germline mutations) with at least two living first degree relatives
diagnosed with invasive melanoma and ascertained through health
care professionals or self-referrals. Two adult controls were
selected for each case, including blood-related or unrelated family
members. The study was approved by the National Cancer
Institute Clinical Center Institutional Review Board and all
subjects gave informed consent. Genotyping was conducted using
the same iSelect Illumina Infinium custom array at the NCI Core
Genotyping Facility.
The second study was a hospital-based case-control study of
non-Hispanic white subjects recruited at the MD Anderson
Cancer Center [20]. Specifically, there were 1,804 melanoma
cases and 1,026 cancer-free controls (friends or acquaintances of
patients reporting to other clinics), who were frequency-matched
on age and sex, completed a comprehensive skin and lifestyle
questionnaire, and whose DNA passed quality control filters for
genotyping for a genome wide-association study. Genotyping was
conducted at the John Hopkins University Center for Inherited
Disease Research (CIDR), using the Illumina HumanOmni1-
Quad_v1-0_B array. Genotypes were called using the BeadStudio
algorithm. MACH was used to impute ungenotyped SNPs
according to 1000 Genomes Project data using the HapMap2
reference data. Information was not available on dysplastic nevi.
The study was approved by the MD Anderson Institutional
Review Board and all individuals provided informed consent.
Relative Telomere Length Measurements
Information on telomere length was available for 368 subjects
from CCS1 and FS (172 melanoma patients and 196 non-
melanoma subjects). DNA was extracted from peripheral blood
leukocytes. Telomere Length (TL) was measured using a quanti-
tative real-time method described by Cawthon [21]. This method
measures the relative TL in genomic DNA by determining the
ratio of telomere repeat copy number (T) to a single copy gene (the
human beta-globin gene, S) copy number (T/S ratio) in
experimental samples relative to a reference sample. The two
reactions were run in triplicate in two different plates for all
samples. SYBR green dye was used to monitor DNA synthesis
versus background fluorescence, as well as the melting temperature
of the product. Each plate also contained a pool of DNA with
serial 1:2 dilutions to compute a standard curve (1.25 ng to 40 ng).
This standard curve was generated from a serially diluted DNA
pool (obtained from 20 DNA samples randomly selected from the
samples tested in the present study), ranging from 1.25 to 40 ng in
each plate, so that relative quantities of T and S (in nanograms)
could be determined from it. The average of the three T
measurements was divided by the average of the three S
measurements to calculate the average T:S ratio or relative
telomere length [21].
Statistical Analysis
We conducted SNP-based, gene-based, functional group based
and overall association analyses. All computations were done using
the R (version 2.13.2) software. HWE was calculated among
controls using an exact test [22] (Table S1). One of the SNP
genotypes (rs7973425 in the DDX11 region) deviated from
Hardy–Weinberg Equilibrium in the control study population
after correcting for multiple testing and it was excluded from the
analyses (Table S1). Linkage disequilibrium (LD) was estimated
using the r2 measure among the genotyped SNPs, and the
corresponding heatmap was computed using a modified version of
the R statistical package LDheatmap [23].
SNP-based association analysis. For each SNP genotype
separately, we computed an odds ratios (OR) and the correspond-
ing standard errors (SE) for the association with risks of melanoma
using unconditional logistic regression models for each of the case-
control studies separately and conditional logistic regression
(conditioning on family) for the family study, adjusting for age
(continuous) and sex. We assumed an additive model in the
number of minor alleles (i.e., SNP genotypes were coded as 0, 1, or
2) and fitted the genotype with a trend in the logistic models. If the
number of subjects was less than 5 for one genotype, we used
a dominant model. We then combined study-specific ORs using
a random effects meta-analysis [24]. However, similar results were
obtained using fixed effects models (data not shown). We further
adjusted the OR for a ‘‘nevus score’’, comprised of nevus count
and presence of dysplastic nevi. These nevus scores were
computed using factor analysis for those individuals who did not
have missing values on the nevus count and presence of dysplastic
nevi. Adjustment for the nevus score grouped into quartiles yielded
similar OR estimates to those adjusted for only age and sex (Table
S2). Therefore, we presented here only the results from models
adjusting for age and sex. Analyses for the association of risk of
dysplastic nevi (coded as absent or present) with SNPs were
conducted in non-melanoma participants using the same approach
as described above.
Poisson regression models adjusted for age and sex were used to
explore the association between nevus count and the SNPs in
controls from CCS1 and FS to compute incident rate ratios (IRR).
We added a SNP genotype and age interaction to adjust for the
changes of nevus count with age [8]. To account for model
assumptions (and correlations among individuals in the FS), we
used a robust sandwich variance estimator.
Finally, we explored whether the presence of dysplastic nevi
modified the association between SNP genotypes and melanoma
risk by adding an interaction term between dysplastic nevi and
SNP genotypes in the SNP-based analysis. A similar analysis was
conducted for nevus count.
We corrected for multiple testing using the Bonferroni method,
which is likely conservative, because of the correlation across
SNPs. After correction, P-values needed to be lower than
1.0561024 for significance at the 5% level.
Analysis for the replication data sets were conducted as
described above, except for nevus count. In the family study, the
variable was collected as an ordinal variable with four categories
and analyzed using a multinomial model. In the hospital-based
study, nevus count was coded as a binary variable.
Gene-based, group-based and overall association
analysis. SNP-based P-values within a gene region were
combined by means of an adaptive rank truncated product
(ARTP) approach to compute the gene-based P-value [25]. In
this approach, SNP-based P-values within a gene region are
combined using a truncated product method, in which the
truncated point is optimized among a set of candidates. This
Telomeres, Nevi and Melanoma
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product defines a test statistic and the gene-based P-value is the
result of this statistic. Significance of the gene-based P-value was
assessed using a permutation procedure with 10,000 permuta-
tions. This approach allows for LD within a gene region and
allows for flexibility in the number of SNPs to include in the P-
value calculation. Nine SNPs mapped to two different gene
regions each and were included in both gene analyses
(rs4873772 and rs762679 to MCM4 and PRKDC; rs2700,
rs3093942, rs4981158, rs10147163, rs7161611 and rs1713419 to
PARP2 and TEP1). The thirty-nine genes were grouped in
several functional groups [18] and functional group P-values
were computed by combining the SNP-based P-values from the
genes in the corresponding group using the ARTP algorithm.
The overall P-value combined all the SNP-based P-values using
the ARTP package.
Telomere length association analysis. Telomere length
was transformed using natural logarithms. We computed associa-
tions between telomere length and different demographic and sun-
related characteristics among non-melanoma subjects using linear
regression, adjusted for age and study (CCS1 vs. FS). We chose to
adjust for study instead of using meta-analytic estimates, due to the
small number of unaffected subjects with telomere length, leading
to unstable estimates in the study-specific analysis. The association
between telomere length and the risk of melanoma was explored
using unconditional (in CCS1) and conditional (in FS) logistic
regressions adjusting for age and sex using telomere length as
a continuous variable. Study-specific ORs were combined using
a random effects meta-analysis [24].
Results
A total of 796 melanoma cases and 770 unaffected subjects were
included in our genetic analysis. Melanoma patients and non-
melanoma participants were similar in age and sex (Table 1).
Cases were more likely to have increased number of nevi, presence
of dysplastic nevi and to report more sun exposure compared to
unaffected individuals.
SNP-based Findings
The C allele of the SNP rs2721173, located in the gene region
RecQ protein-like 4 (RECQL4), was associated with an increased
risk of melanoma (OR=1.35, 95% CI: 1.13, 1.62; P-
trend= 1.1361023; Figures S1 and S2 and Tables S2 and S3).
Presence of dysplastic nevi was most strongly associated with the G
allele of the SNP rs6011002 (OR=3.30, 95% CI: 1.64, 6.61; P-
trend= 7.7561024; Figures S3 and S4 and Tables S4 and S5),
which is located in the regulator of telomere elongation helicase 1
(RTEL1) gene region. After Bonferroni correction, nevus count
was significantly associated with the T allele of the SNP
rs11955168 located in the RAD50 region (IRR=2.79; 95% CI:
1.77, 4.38; P-trend= 8.6861026; Figure S5 and Table S6) and
with the A allele of the SNP rs11850456 in the telomerase-
associated protein 1 (TEP1) region (IRR=0.41; 95% CI: 0.26,
0.64; P-trend= 1.0461024; Figure S5 and Table S7). Two SNPs,
rs153045 and rs251796, in the TERF2 region, implicated in the
protection of telomeres, that were previously found to be
correlated with the number of nevi, were significantly associated
with higher number of nevi in our study (IRR=1.49; 95% CI: 1.2,
1.85; P-trend= 3.2761024 for rs153045; IRR=1.32, 95% CI:
1.06, 1.66; P-trend= 0.01 for rs251796; Figures S5 and S6 and
Tables S8, S9 and S10).
Analyses including interaction terms between SNP genotypes
and the presence of dysplastic nevi or nevus count on the risk of
melanoma yielded non-statistically significant results.
Our findings in the Italian study were not replicated in the two
American datasets. In the US family study, which comprised 562
individuals (183 melanoma cases) from 53 melanoma-prone
families, the C allele of rs2721173 in RECQL4 decreased the
risk of melanoma by 17% (OR=0.83, 95% CI: 0.36, 1.16; P-
trend= 0.34), but did not reach statistical significance. In the
hospital-based case-control study, comprised of 1,804 melanoma
cases and 1,026 cancer free controls, the C allele of rs2721173 was
not associated with melanoma risk (OR=0.92, 95% CI: 0.79,
1.03; P-trend= 0.16). Similarly, SNP rs6011002 in RTEL1 was
not associated with the presence of dysplastic nevi (OR=0.65,
95% CI: 0.33, 1.29; P-trend= 0.22) in the family study (presence
of dysplastic nevi was not available in the hospital-based case-
control study). The SNP rs11955168 in RAD50 was not
significantly associated with nevus count in the US family study
(OR=0.45, 95% CI: 0.10, 1.93; P-trend= 0.28) nor in the
hospital-based study (OR=1.37, 95% CI: 0.67, 2.83; P-
trend= 0.39). Similarly, SNP rs11850456 in TEP1was not
significantly associated with nevus count in the US family-study
(OR=0.76, 95% CI: 0.23, 2.54; P-trend= 0.66) nor in the
hospital-based case-control study (OR=0.77, 95% CI: 0.47, 1.29;
P-trend= 0.32), although in the Italian and the two American
studies it was associated with a reduced risk. The two SNPs that
were previously reported to be significantly correlated with nevus
count and that were significantly associated with number of nevi in
our study were not associated in the two American studies,







,30 93 (11.7) 106 (13.8)
30–39 142 (17.9) 147 (19.1)
40–49 152 (19.1) 161 (21.0)
50–59 174 (21.9) 144 (18.8)
$60 234 (29.4) 210 (27.3)
Sex
Males 377 (47.4) 381 (49.5)
Females 419 (52.6) 389 (50.5)
Nevus count
,10 244 (32.8) 238 (36.4)
10–50 289 (38.9) 308 (47.1)
.50 210 (28.3) 108 (16.5)
Dysplastic nevi
No 457 (62.4) 463 (74.8)
Yes 275 (37.6) 156 (25.2)
Chronic sun exposure*
No 467 (67.3) 343 (72.8)
Yes 227 (32.7) 128 (27.2)
Intermittent sun exposure
Very little 237 (30.0) 227 (32.5)
Some 299 (37.9) 313 (44.8)
High 253 (32.1) 158 (22.6)
Numbers might no add to totals due to missing values. Data might not add up
to 100% because of rounding.
*Not measured in the family study.
doi:10.1371/journal.pone.0052466.t001
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although the different categorization of nevus count and analysis
techniques used in the different studies make difficult to directly
compare them.
Gene-based Findings
Similar to the SNP-based findings, the RECQL4 region had the
strongest association with the risk of melanoma (gene-based P-
value = 2.561023; Table 2, Table S2 and Figure S2) and the
RTEL1 region had the strongest association with risk of dysplastic
nevi (gene-based P-value = 0.004; Table 3, Table S3 and Figure
S4). The TERF2 region had the strongest association with nevus
count (gene-based P-value = 0.009; Table 3, Table S4 and Figure
S6).
Functional Pathway-based Findings
We categorized the 39 genes into five different functional
groups, as in Mirabello et al. [18] (Table S11). Similar to the gene-
based results, the helicase subgroup, which included the RECQL4
region, was associated with melanoma risk (P = 0.03); a telomere
related group, which included the RTEL1 region, was associated
with dysplastic nevi (P = 0.11); and the shelterin subgroup, which
included the TERF2 region, was associated with nevus count
(P = 0.09).
In an analysis that combined p-values from all of the SNPs in
the 39 telomere-related genes into a single summary p-value, we
found no association with the risk of melanoma (overall P-
value = 0.17), dysplastic nevi (overall P-value = 0.24) or nevus
count (overall P-value = 0.17).
Telomere Length
The telomere length analysis was based on 172 melanoma
patients and 196 non-melanoma subjects from two studies (CCS1
and FS). A box-plot showing the distribution of telomere length
among cases and unaffected individuals is available online (Figure
S7). Among non-melanoma cases, telomere length was associated
with age (P-trend: 4.7261024; Table 4), but was not associated
with sex, nevus count, dysplastic nevi, or sun exposure. Further-
more, it was not significantly associated with the risk of melanoma
(OR=0.87; 95% CI: 0.46–1.64). In our study, telomere length
was not associated with any of the selected SNPs among unaffected
individuals (Figure S8).
Discussion
In the current study, we combined data from three case-control
studies and one family study conducted in Italy, and examined the
associations of 39 genes related to the biology of telomeres, and
475 SNPs within these genes, with the risk of melanoma, presence
of dysplastic nevi, number of nevi and telomere length.
The gene regions around RECQL4, RTEL1 and TERF2 were
associated with melanoma, the presence of dysplastic nevi and
number of nevi, respectively, in the Italian combined study.
However, we did not find the same associations in two American
studies with different study designs.
Previously, among the telomere-related genes, two SNPs in
TERT, rs2853676 and rs2242652, were reported to have
a significant association with melanoma in a Caucasian population
[9]. However, these SNPs were not associated with melanoma in
our population (OR=1.17; 95% CI: 0.84, 1.63 for rs2853676;
OR=0.96; 95% CI: 0.66, 1.39 for rs2242652). Furthermore, the
same study also reported two SNPs in TERF2 (rs153045 and
rs251796) that were significantly correlated with number of nevi,
but they did not report the size of the association after adjustment
for confounding variables. We found that these two SNPs were
significantly associated with higher number of nevi in our study. In
the gene-based analysis, the TERF2 region had the strongest
association with nevus count, suggesting that further research into
this gene region and its role in nevi development may prove
informative.
Shorter telomere length measured in prediagnostic blood
samples was previously found to be correlated with number of
Table 2. Gene-based association analysis with the risk of
melanoma.








































*Based on a meta-analysis of the three case-control studies and one family
study. Model was adjusted for age (continous) and sex. Genes ordered from
most significant to least significant associations with outcome.
doi:10.1371/journal.pone.0052466.t002
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nevi (P = 0.002) and associated with a reduced risk of melanoma,
although not significantly (P-trend= 0.09) [7]. In a recent com-
bined analysis of 3 prospective studies, shorter telomere length was
associated with a reduced risk of melanoma (P-trend= 0.0003) [6].
In our study, shorter telomere length was not associated with
number of nevi, but similar to the previous two analyses, telomere
length was associated with a decreased risk of melanoma, although
it did not reach statistical significance. Measurements of telomere
length in our study were performed in samples collected
retrospectively. However, this is unlikely to play an important
role in our findings since one would have expected to observe
Table 3. Gene-based association analysis and risk of dysplastic nevi and number of nevi in unaffected subjects.
Dysplastic nevi Nevus count
Gene Number of SNPs in gene P-value* Gene Number of SNPs in gene P-value**
RTEL1 12 4.261023 TERF2 7 8.661023
RAD54L 9 0.02 DDX1 10 0.01
PINX1 29 0.07 MEN1 8 0.04
NBN 17 0.10 TEP1 37 0.05
RECQL4 5 0.13 TERC 3 0.05
MYC 20 0.14 PARP2 19 0.05
RAD50 12 0.18 RAD50 14 0.10
RAD51AP1 13 0.21 RECQL4 5 0.21
PARP2 19 0.22 NOLA2 5 0.26
RAD51L3 13 0.22 MYC 20 0.31
NOLA2 5 0.24 RAD51L3 13 0.31
MEN1 7 0.28 RAD51AP1 13 0.36
TERC 3 0.32 RTEL1 13 0.39
TNKS 37 0.33 ATM 12 0.46
XRCC6 4 0.34 RAD51C 6 0.47
PRKDC 7 0.38 MCM4 2 0.50
DDX11 4 0.41 TNKS 37 0.50
MCM4 2 0.43 NOLA3 14 0.51
RECQL5 4 0.46 TNKS2 5 0.56
DDX1 10 0.46 TINF2 9 0.57
TEP1 37 0.48 ACD 3 0.60
RAD51C 6 0.48 WRN 16 0.60
TERF2 7 0.57 PINX1 29 0.60
NOLA1 8 0.60 XRCC6 4 0.63
POT1 5 0.62 DDX11 4 0.67
TNKS2 5 0.65 PARP1 23 0.67
BLM 26 0.65 PRKDC 7 0.74
ACD 3 0.65 TERF1 14 0.78
ATM 12 0.67 RECQL 21 0.79
TERF1 14 0.74 RAD54L 9 0.83
PARP1 23 0.84 PIK3C3 3 0.87
WRN 16 0.84 TERT 12 0.88
NOLA3 14 0.85 POT1 5 0.91
TERT 12 0.87 NOLA1 8 0.92
MRE11A 17 0.89 BLM 28 0.93
PIK3C3 3 0.93 MRE11A 17 0.94
RECQL 21 0.95 TERF2IP 7 0.96
TERF2IP 7 0.95 NBN 17 0.97
TINF2 9 0.99 RECQL5 4 0.98
*Based on a meta-analysis of the 3 case-control studies and the family study. Model was adjusted for age (continous) and sex.
**Based on a meta-analysis of case-control study and the family study using Poisson regression with robust variance. Model was adjusted for age (continous) and sex
and interaction between age and SNP genotype. Genes ordered from the most to the least significant P-value.
doi:10.1371/journal.pone.0052466.t003
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a positive association with the risk of melanoma and we did not
observe such an association.
This is the most comprehensive study of telomere-related genes
and melanoma risk to date. In addition, we explored the
associations between telomere length and nevi (dysplastic nevi
and number of nevi). Further, we used gene-set and pathway
approaches that allowed us to maximize our ability to detect effects
that were only significant at the aggregate level, and not at the
SNP level. We combined both case-control and family studies and
assessed multiple variants in detail. However, the assessment of
different characteristics, such as the number of nevi, could vary
across studies and could have affected our measurements. For this
reason, we performed analyses regarding number of nevi in the
two studies (CCS1 and FS) in which skin examinations were
performed by the same doctor. Moreover, we only considered the
variable of presence/absence of dysplastic nevi instead of their
number. Furthermore, we accounted for the potential heteroge-
neity in the studies by computing meta-analytic estimates, instead
of pooling the data together. It is known that the number of nevi
changes through the lifetime of an individual, with nevi count
reaching its maximum around 35–40 years of age [8]. This could
result in misclassification, leading to attenuated results. However,
we included an interaction term between the number of nevi and
age in our models to account for this effect modification by age.
Our findings may suggest a role for telomere-related genes in
melanoma risk as observed for other cancers [26–29] and add
insights into the complex biology of telomeres in melanoma
development. However, despite the strengths of our study, our
results were not confirmed in the two US populations, including
a melanoma family study and a hospital-based case-control study.
Differences in the ascertainment of nevi in the replication studies
and related analyses could partially explain these results.
Mediterranean populations generally differ from American and
Australian populations, which experience a higher incidence of
melanoma, in terms of pigmentation characteristics, intensity of
sun exposure and genetic susceptibility [30]. These factors may
also explain some discrepancies, but as in any epidemiological
investigation, chance findings cannot be completely ruled out.
Larger studies are needed to explore the role of these factors in
relation to telomere genes and melanoma risk.
In summary, our results suggest that telomere-related genes
might be related to the susceptibility of melanoma, dysplastic nevi









Table 4. Relationship of telomere length with demographic and sun related characteristics in non-melanoma subjects.
Characteristics Unaffected (N=196) n (%) Mean telomere length and 95% CI1 P-trend1
Age (years) 4.7261024
,30 33 (16.9) 1.00 (ref.)
30–39 43 (22.1) 0.94 (0.80, 1.12)
40–49 43 (22.1) 0.89 (0.75, 1.06)
50–59 43 (22.1) 0.87 (0.73, 1.03)
$60 33 (16.9) 0.73 (0.61, 0.87)
Sex 0.85
Males 97 (49.5) 1.00 (ref.)
Females 99 (50.5) 0.99 (0.89, 1.10)
Nevus count 0.76
,10 26 (14.1) 1.00 (ref.)
10–50 111 (60.3) 0.90 (0.77, 1.06)
.50 47 (25.5) 0.99 (0.83, 1.19)
Dysplastic nevi 0.85
No 120 (71.4) 1.00 (ref.)
Yes 48 (28.6) 1.01 (0.88, 1.16)
Chronic sun exposure* 0.13
No 90 (55.6) 1.00 (ref.)
Yes 72 (44.4) 0.92 (0.82, 1.03)
Intermittent sun exposure 0.57
Very little 57 (29.1) 1.00 (ref.)
Some 92 (46.9) 0.95 (0.84, 1.08)
High 47 (24.0) 0.96 (0.83, 1.11)
Data might not add up to 100% because of rounding.
1Compute only among unaffected individuals. Mean is the geometric mean. Adjusted by age and study (CCS1 vs. FS).
*Not measured in the family study.
doi:10.1371/journal.pone.0052466.t004
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